home / stock / otlkw / otlkw quote
Last: | $0.03 |
---|---|
Change Percent: | -1.96% |
Open: | $0.02 |
Close: | $0.03 |
High: | $0.035 |
Low: | $0.01 |
Volume: | 156,240 |
Last Trade Date Time: | 02/16/2022 04:55:25 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.03 | $0.02 | $0.03 | $0.035 | $0.01 | 156,240 | 02-16-2022 |
$0.0306 | $0.04 | $0.0306 | $0.04 | $0.02 | 122,537 | 02-15-2022 |
$0.041 | $0.05 | $0.041 | $0.05 | $0.025 | 18,641 | 02-14-2022 |
$0.0499 | $0.0798 | $0.0499 | $0.096 | $0.02 | 78,034 | 02-11-2022 |
$0.076 | $0.04 | $0.076 | $0.0797 | $0.0351 | 181,066 | 02-10-2022 |
$0.0341 | $0.0356 | $0.0341 | $0.0378 | $0.034 | 29,212 | 02-09-2022 |
$0.0356 | $0.029 | $0.0356 | $0.0356 | $0.0125 | 3,151 | 02-08-2022 |
$0.0369 | $0.039 | $0.0369 | $0.039 | $0.029 | 12,311 | 02-07-2022 |
$0.0394 | $0.03 | $0.0394 | $0.0394 | $0.0297 | 7,399 | 02-04-2022 |
$0.029 | $0.0303 | $0.029 | $0.0305 | $0.029 | 11,304 | 02-03-2022 |
$0.0405 | $0.0302 | $0.0405 | $0.0416 | $0.0302 | 4,238 | 02-02-2022 |
$0.0416 | $0.0304 | $0.0416 | $0.0416 | $0.0304 | 26,501 | 02-01-2022 |
$0.0425 | $0.0425 | $0.0425 | $0.0425 | $0.04 | 34,160 | 01-31-2022 |
$0.0293 | $0.049899 | $0.0293 | $0.0499 | $0.0293 | 3,925 | 01-28-2022 |
$0.0499 | $0.049 | $0.0499 | $0.05 | $0.0425 | 13,422 | 01-26-2022 |
$0.0348 | $0.044 | $0.0348 | $0.0473 | $0.0348 | 30,091 | 01-25-2022 |
$0.049 | $0.0488 | $0.049 | $0.049 | $0.0488 | 3,111 | 01-24-2022 |
$0.0441 | $0.0448 | $0.0441 | $0.0499 | $0.0415 | 76,750 | 01-21-2022 |
$0.045 | $0.0412 | $0.045 | $0.0454 | $0.0412 | 32,973 | 01-20-2022 |
$0.0412 | $0.04 | $0.0412 | $0.0425 | $0.021 | 29,932 | 01-19-2022 |
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Series A Warrant Company Name:
OTLKW Stock Symbol:
NASDAQ Market:
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the fi...
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed...
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the fir...